When was Sanoptis founded?

Sanoptis was founded in 2018 and raised its 1st funding round 7 years after it was founded.

Where is Sanoptis located?

Sanoptis is headquartered in Zug, Switzerland.

Who is the current CEO of Sanoptis?

Volker Wendel of Sanoptis. They are also an angel investors in 1 startup.

How many employees does Sanoptis have?

As of Jun 30, 2026, the latest employee count at Sanoptis is 147.

Is Sanoptis a funded company?

Sanoptis is a funded company, having raised a total of €***** in its 1st and only funding round, a PE round on Mar 25, 2025.

When was the latest funding round of Sanoptis?

Sanoptis' latest funding was a €***** PE round on Mar 25, 2025, with participation from 1 investor.

Where does Sanoptis rank among its competitors?

Sanoptis ranks 18th amongst 71 active competitors, of which 10 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Sanoptis, which secured an undisclosed amount in Mar, 2025.

Who are the top competitors of Sanoptis?

Sanoptis' top competitors include Ziemer Ophthalmology, Perfuse Therapeutics and IRIDEX. Among them, Sanoptis secured the most recent funding round in March, 2025.

Sanoptis - 2026 Company Profile, Team, Funding & Competitors

Sanoptis is an acquired company based in Zug (Switzerland), founded in 2018. It operates as a Network of eye clinics and practices offering ophthalmological services.. Sanoptis has raised $270M in funding from The Carlyle Group. The company has 71 active competitors, including 10 funded and 20 that have exited. Its top competitors include companies like Ziemer Ophthalmology, Perfuse Therapeutics and IRIDEX.

Company Details

Network of eye clinics and practices offering ophthalmological services. It provides a platform for modern eye clinics and practices. The company facilitates collaborations, investments, and training for improved patient care. It fosters knowledge sharing among medical professionals. The company supports recruitment and development of medical staff. It advises clinics and practices on optimizing operations, personnel, finance, and marketing. The company invests in equipment and facilities to ensure treatment in a comfortable environment.

Website: sanoptis.com
Email ID: *****@sanoptis.com
Phone Number: +41 **********

Key Metrics

Founded Year

2018

Location

Zug, Switzerland

Stage

Acquired

Total Funding

$270M in 1 round

Latest Funding Round

PE, Mar 25, 2025, €*****

Investors

The Carlyle Group

Ranked

18^th among 71 active competitors

Employee Count

147 as on Jun 30, 2026

Investment & Acquisitions

Skleo & 1 more

Similar Companies

Ziemer Ophthalmology & 81 more

Exit Details

Acquired by GBL (Apr 20, 2022)

View Sanoptis' full profile

Sanoptis got acquired by GBL on Apr 20, 2022.

Click here to take a look at Sanoptis's acquisition in detail

Sanoptis has raised a total funding of $270M over 1 round. Its latest funding round was a PE round on Mar 25, 2025 for €*****. 1 investor participated in its latest round. Sanoptis has 1 institutional investor.

Here is the list of recent funding rounds of Sanoptis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 25, 2025	7928328	PE	1988499	3275489	1410330	8825843

Access funding benchmarks and valuations. Sign up today!

View details of Sanoptis's funding rounds and investors

Sanoptis' employee count trend

Sanoptis has 147 employees as of Jun 26. Here is Sanoptis's employee count trend over the years:

Uncover Sanoptis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Sanoptis include Ziemer Ophthalmology, Perfuse Therapeutics and IRIDEX. Here is the list of Top 10 competitors of Sanoptis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ziemer Ophthalmology 2005, Basel (Switzerland), Series B	Portfolio of devices for refractive and corneal surgery	$17.4M	BV Partners, HBM Partners & 1 others	52/100
2nd	Perfuse Therapeutics 2018, San Francisco (United States), Acquired	Developer of therapies to treat eye disorders	-	Access Industries, Lilly Asia Ventures & 3 others	49/100
3rd	IRIDEX 1989, Mountain View (United States), Public	Manufacturer of ophthalmic laser systems and surgical instruments for eyes	-	New Enterprise Associates, Incubic & 1 others	47/100
4th	MicroSurgical Technology 1976, Redmond (United States), Acquired	Develops a portfolio of Surgical tools for Ophthalmic surgeries	-	-	47/100
5th	Dopavision 2017, Berlin (Germany), Series A	Developer of a digital therapeutic for myopia	$17.4M	Boehringer Ingelheim Venture Fund, Seventure Partners ... & 9 others	45/100
6th	Keeler 1917, Windsor (United Kingdom), Unfunded	A portfolio of ophthalmic devices	-	-	44/100
7th	Oertli Instrumente 1955, Berneck (Switzerland), Unfunded	Developer of ophthalmology medical device	-	-	44/100
8th	Lalji International 2018, Ahmedabad (India), Unfunded	Manufacturer of disposable medical drapes and surgical gowns. The company produces a variety of products for various medical applications, including ophthalmology, gynecology, and general surgery. These products are designed for single-use and contribute to maintaining a sterile environment during procedures. The manufacturing process emphasizes quality control to ensure the safety and efficacy of the products. The company's offerings also include hospital beds and related furniture.	-	-	42/100
9th	Lamellar 2007, Glasgow (United Kingdom), Series C	Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies	$18.4M	Hambro Perks, Invesco & 4 others	42/100
10th	Katena 1975, Tampa (United States), Acquired	Ophthalmic surgical products for sight restoration, clinician support, and patient care	$7.5M	Audax Private Equity	40/100
18th	Sanoptis 2018, Zug (Switzerland), Acquired	Network of eye clinics and practices offering ophthalmological services.	$270M	The Carlyle Group	35/100